注意缺陷多动障碍药物心血管安全性比较:系统综述与网络荟萃分析
该网络荟萃分析纳入102项短期随机对照试验,比较9种ADHD药物在儿童青少年及成人中对血压和脉搏的影响。多种药物可致血流动力学指标升高,胍法辛则降低这些指标;指南建议对所有接受药物治疗的ADHD患者监测血压和脉搏。
要点
- 安非他明类、托莫西汀、赖氨酸安非他明、哌甲酯和维洛嗪在儿童青少年或成人中均可致血流动力学指标升高。
- 胍法辛在儿童青少年和成人中均与血压和脉搏降低相关。
- 现有随机对照试验随访时间短(中位7周),缺乏长期心血管安全性证据。
核心结论
- 临床医生应对使用任何药物治疗的ADHD患者监测血压和脉搏,而不仅限于兴奋剂。
研究设计与样本
- 系统综述与网络荟萃分析,检索12个电子数据库至2024年1月18日,纳入102项随机对照试验。
- 纳入13 315名儿童青少年(平均年龄11岁)和9387名成人(平均年龄35岁),随访中位7周。
- 比较安非他明类、托莫西汀、安非他酮、可乐定、胍法辛、赖氨酸安非他明、哌甲酯、莫达非尼或维洛嗪与安慰剂或彼此之间的效果。
关键数值与推荐
- 主要结局为收缩压、舒张压(mm Hg)和脉搏(次/分)较基线的变化,取接近12周、26周和52周的时间点。
临床怎么用
- 对接受药物治疗的ADHD患者常规监测血压和脉搏,而非仅监测兴奋剂使用者。
局限性
- 仅4项随机对照试验提供中期效果,无长期效果数据。
- 纳入试验随访时间短,中位仅7周。
- 成人中多项结局的CINeMA证据确信度极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concerns about the cardiovascular safety of medications used for the treatment of attention-deficit hyperactivity disorder (ADHD) remain. We aimed to compare the effects of pharmacological treatments for ADHD on haemodynamic values and electrocardiogram (ECG) parameters in children, adolescents, and adults. METHODS: For this systematic review and network meta-analysis, we searched 12 electronic databases, including Cochrane CENTRAL, Embase, PubMed, and the WHO International Clinical Trials Registry Platform, from database inception to Jan 18, 2024, for published and unpublished randomised controlled trials comparing amphetamines, atomoxetine, bupropion, clonidine, guanfacine, lisdexamfetamine, methylphenidate, modafinil, or viloxazine against each other or placebo. Primary outcomes were change in systolic blood pressure (SBP) and diastolic blood pressure (DBP), measured in mm Hg, and pulse, measured in beats per minute, at timepoints closest to 12 weeks, 26 weeks, and 52 weeks. Summary data were extracted and pooled in random-effects network meta-analyses. Certainty of evidence was assessed with the Confidence in Network Meta-Analysis (CINeMA) framework. This study was registered with PROSPERO, CRD42021295352. Before study initiation, we contacted representatives of a UK-based charity of people with lived experience of ADHD-the ADHD Foundation-regarding the relevance of the topic and the appropriateness of the outcomes chosen. FINDINGS: 102 randomised controlled trials with short-term follow-up (median 7 weeks [IQR 5-9]) were included, encompassing 13 315 children and adolescents (aged ≥5 years and <18 years; mean age 11 years [SD 3]; of available data, 9635 [73%] were male and 3646 [27%] were female; of available data, 289 [2%] were Asian, 1719 [15%] were Black, and 8303 [71%] were White) and 9387 adults (≥18 years, mean age 35 years [11]; of available data, 5064 [57%] were male and 3809 [43%] were female; of available data, 488 [6%] were Asian, 457 [6%] were Black, and 6372 [79%] were White). Amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine led to increments in haemodynamic values in children and adolescents, adults, or both. In children and adolescents, mean increase against placebo ranged from 1·07 (95% CI 0·36-1·79; moderate CINeMA confidence) with atomoxetine to 1·81 (1·05-2·57; moderate) with methylphenidate for SBP; from 1·93 (0·74-3·11; high) with amphetamines to 2·42 (1·69-3·15; low) with methylphenidate for DBP; and from 2·79 (1·05-4·53; moderate) with viloxazine to 5·58 (4·67-6·49; high) with atomoxetine for pulse. In adults, mean increase against placebo ranged from 1·66 (95% CI 0·38-2·93; very low) with methylphenidate to 2·3 (0·66-3·94; very low) with amphetamines for SBP; from 1·60 (0·29-2·91; very low) with methylphenidate to 3·07 (0·69-5·45; very low) with lisdexamfetamine for DBP; and from 4·37 (3·16-5·59; very low) with methylphenidate to 5·8 (2·3-9·3; very low) with viloxazine for pulse. Amphetamines, lisdexamfetamine, or methylphenidate were not associated with larger increments in haemodynamic values compared with atomoxetine or viloxazine in either children and adolescents or adults. Guanfacine was associated with decrements in haemodynamic values in children and adolescents (mean decrease against placebo of -2·83 [95% CI -3·8 to -1·85; low CINeMA confidence] in SBP, -2·08 [-3 to -1·17; low] in DBP, and -4·06 [-5·45 -2·68; moderate] in pulse) and adults (mean decrease against placebo of -10·1 [-13·76 to -6·44; very low] in SBP, -7·73 [-11·88 to -3·58; very low] in DBP, and -6·83 [-10·85 to -2·81; very low] in pulse). Only four RCTs informed on effects in the medium term and none on the long term. INTERPRETATION: Practitioners should monitor blood pressure and pulse in patients with ADHD treated with any pharmacological intervention, and not stimulants only. Given the short duration of available randomised controlled trials, new research providing insights on the causal effects of ADHD medications on cardiovascular parameters in the longer term should be funded. FUNDING: National Institute for Health and Care Research.
引用
- Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025. PMID: 40203844. doi:10.1016/S2215-0366(25)00062-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。